SNV 1
Alternative Names: CDL 201; CLD-201; SN-V1c; SN-V1sa; SNV1; SuperNova-1Latest Information Update: 25 Apr 2025
At a glance
- Originator Calidi Biotherapeutics
- Class Antineoplastics; Immunotherapies; Mesenchymal stem cell therapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 17 Apr 2025 Calidi Biotherapeutics plans a phase I/II trial for Solid tumours (Late-stage disease, Metastatic disease, In adults), in the third quarter of 2025
- 17 Apr 2025 US FDA approves IND application for SNV 1 in Solid tumours
- 31 Mar 2025 Calidi Biotherapeutics files an IND application for Solid tumours (Late-stage disease, Metastatic disease)